GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » KPC Pharmaceuticals Inc (SHSE:600422) » Definitions » 5-Year Yield-on-Cost %

KPC Pharmaceuticals (SHSE:600422) 5-Year Yield-on-Cost % : 2.00 (As of May. 04, 2025)


View and export this data going back to 2000. Start your Free Trial

What is KPC Pharmaceuticals 5-Year Yield-on-Cost %?

KPC Pharmaceuticals's yield on cost for the quarter that ended in Mar. 2025 was 2.00.


The historical rank and industry rank for KPC Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:

SHSE:600422' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.66   Med: 2.27   Max: 4.25
Current: 2


During the past 13 years, KPC Pharmaceuticals's highest Yield on Cost was 4.25. The lowest was 0.66. And the median was 2.27.


SHSE:600422's 5-Year Yield-on-Cost % is ranked worse than
54.86% of 514 companies
in the Drug Manufacturers industry
Industry Median: 2.22 vs SHSE:600422: 2.00

Competitive Comparison of KPC Pharmaceuticals's 5-Year Yield-on-Cost %

For the Drug Manufacturers - Specialty & Generic subindustry, KPC Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KPC Pharmaceuticals's 5-Year Yield-on-Cost % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, KPC Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where KPC Pharmaceuticals's 5-Year Yield-on-Cost % falls into.


;
;

KPC Pharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of KPC Pharmaceuticals is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

KPC Pharmaceuticals  (SHSE:600422) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


KPC Pharmaceuticals 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of KPC Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


KPC Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 166 Keyi Road, State New and High-Technology Development Zone, Kunming, Yunnan, CHN, 650106
KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.
Executives
Qu Xiao Ru senior management
Xie Bo senior management
Meng Li senior management
Zhong Xiang Gang senior management
Wu Sheng Long senior management
Liu Jun Feng senior management
Wang Lei senior management
Zhang Meng Xun senior management
Hu Zhen Bo senior management
Sun Lei senior management
Xu Chao Neng senior management
Wang Jun senior management
Zhao Jian senior management
He Qin Director
Dai Xiao Chang senior management

KPC Pharmaceuticals Headlines

No Headlines